Interest of Virtual Reality to Reduce Patient Anxiety During the Placement of a Percutaneous Implantable Port Catheter (RV-CIP)

December 21, 2023 updated by: Hospices Civils de Lyon

The Vascular Access Unit (UAV) of the Lyon Sud Hospital Center is the first unit within a French public establishment where the Regional Health Agency (ARS) has authorized that medical procedures for the installation of central venous access be performed by nurses.

The installation of CIP represents an anxiety-provoking step for the patient, because the gesture, which consists of inserting a box under the skin, connected to a catheter, placed in a deep vein, involves uncomfortable, even painful moments. In the UAV, the installation of this device is carried out in the operating room, without premedication and only under local anesthesia. Affected patients usually have a diagnosis of serious illness (oncology).

Virtual Reality (VR) simulates the physical presence of the patient in an environment artificially generated by software. Many applications have already been evaluated in different health sectors, the investigators would like to show its interest in reducing patient anxiety during CIP placement under local anesthesia, without premedication.

The medical device used is Lumeen. It is a Class I medical device software within the meaning of Regulation (EU) 2017/745, CE marked. In the context of research, the Relaxation module is used. This module is the one intended for the management of anxiety and pain induced by medical procedures in adults and children over 6 years of age. It allows to perform immersions in 360° videos in real shots or computer-generated images, accompanied by natural sounds, relaxing music and a relaxation script recorded by hypnotherapists. The duration of an immersion can be adjusted according to the needs of the medical procedure..

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Pierre Bénite, France, 69495
        • Unité d'Accès Vasculaire/Secteur Anesthésie Blocs - CHLS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patient ≥18 years old
  • Patient operated on an outpatient basis and available for a phone call between D+1 and D+5
  • Patient operated for a 1st pose of CIP at the UAV
  • Patient whose anxiety measured by ENS Anxiety is at least 4/10 at entry
  • Patient having signed the Informed Consent
  • Patient affiliated to a social security

Exclusion Criteria:

  • Patient not sufficiently fluent in the French language, in the judgment of the investigator, to allow him a good understanding of the implementation and the interest of the virtual reality headset material;
  • Patient with motion sickness;
  • Patient participating in another study who, in the judgment of the investigator, could interfere with the results of this research protocol;
  • Patient deprived of liberty or placed under guardianship or curators;
  • Pregnant or breastfeeding women;
  • Patient with a history of epilepsy ;
  • Patient with a pacemaker or pacemaker;
  • Patient with psychiatric disorders of a psychotic nature in the acute phase or visual hallucinations;
  • Patient under anxiolytic treatment;
  • Patient presenting wounds or infections on the level of the head not allowing the installation of the virtual reality helmet.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CIP procedure under virtual reality

When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.

Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.

The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Description of Patient's anxiety through his participation
Time Frame: through study completion, an average of 5 days
Evaluated by Simple Numerical Scale : Anxiety from 0 to 10
through study completion, an average of 5 days
Evolution of Patient's anxiety during the procedure
Time Frame: Day 0
Evaluated by Simple Numerical Scale : Anxiety from 0 to 10
Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of virtual reality on the pain perceived by the patient;
Time Frame: Day 0 (after placing the port)
The patient's pain, over the entire procedure, measured by Simple Numerical Scale : Pain from 0 to 10
Day 0 (after placing the port)
Effects of virtual reality on Pulse
Time Frame: Day 0 (before, during and after placing the port)
The Pulse of the patient
Day 0 (before, during and after placing the port)
Effects of virtual reality on Blood Pressure
Time Frame: Day 0 (before, during and after placing the port)
The Blood Pressure of the patient (both systolic and diastolic)
Day 0 (before, during and after placing the port)
Effects of virtual reality on memorization of the gesture
Time Frame: Day 0 (after placing the port) and through study completion between D+1 and D+5
Measured by a Likert scale (Likert scale = Very Uncomfortable- Uncomfortable- Comfortable- Very Comfortable)
Day 0 (after placing the port) and through study completion between D+1 and D+5
Effects of virtual reality on the perception of time
Time Frame: Day 0 (after placing the port)
Perception of time in minutes estimated by the patient (In your opinion, how long did the gesture last? and difference with the actual duration of the gesture
Day 0 (after placing the port)
Effects of virtual reality on satisfaction and comfort during installation
Time Frame: Day 0 (after placing the port)
Measured by a Simple Numerical Scale from 0 to 10
Day 0 (after placing the port)
Effects of virtual reality on the caregiver's perception of the ease of the gesture
Time Frame: Day 0 (after placing the port)
Measured by a Likert scale, (Likert scale = Easy-patient Immobile - appearing relaxed / Moderately Easy-Patient slightly mobile- Reactive / Difficult-Patient having difficulty in staying Still- Very reactive- Seeming tense)
Day 0 (after placing the port)
Effects of virtual reality on caregiver satisfaction
Time Frame: Day 0 (after placing the port)
Measured by a Simple Numerical Scale from 0 to 10
Day 0 (after placing the port)
Effects of virtual reality on the duration of the intervention
Time Frame: Day 0 (after placing the port)
Duration of the procedure in minutes between the patient entering and leaving the operating room
Day 0 (after placing the port)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Annie de FILIPPIS, HCL

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2023

Primary Completion (Actual)

December 20, 2023

Study Completion (Actual)

December 20, 2023

Study Registration Dates

First Submitted

August 24, 2022

First Submitted That Met QC Criteria

August 30, 2022

First Posted (Actual)

September 2, 2022

Study Record Updates

Last Update Posted (Actual)

December 22, 2023

Last Update Submitted That Met QC Criteria

December 21, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 69HCL19_0824

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe